European Patent Office (EPO) publication EP3981790A1 details a patent application filed by Jacobio Pharmaceuticals Co., Ltd. for a CD73 binding molecule and its therapeutic uses, particularly in treating cancer. The publication includes inventor names, International Patent Classification (IPC) codes related to peptides, antibodies, and pharmaceutical compositions, and lists designated states within the European patent region.

This document serves as a public notice of the patent application. While it does not impose immediate compliance obligations on regulated entities, it is crucial for pharmaceutical and biotechnology companies to monitor patent filings in their areas of research and development. Understanding the scope of this patent application could inform competitive strategies and potential licensing or infringement considerations.